Does Lumacaftor And Ivacaftor Interact with Itraconazole?
CDI records a moderate classification for Lumacaftor And Ivacaftor and Itraconazole. The stored summary is: Strong CYP3A inhibitor increases ivacaftor exposure 4.3-fold. Dosage adjustment needed when initiating ORKAMBI in patients taking itraconazole. The mechanism involves cyp3a inhibition increases ivacaftor exposure; lumacaftor induction effect mitigates at steady-state. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Lumacaftor And Ivacaftor Class
- Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
- Itraconazole Class
- Azole Antifungal
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP3A inhibition increases ivacaftor exposure; lumacaftor induction effect mitigates at steady-state
What To Tell Your Doctor or Pharmacist
If you are taking Lumacaftor And Ivacaftor and your doctor is considering prescribing Itraconazole (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider